Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Clopidogrel is a P2Y12 inhibitor crucial for preventing thrombotic events in patients with ST-elevated myocardial infarction (STEMI).
• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard post-STEMI care.
• Concerns exist regarding the bioequivalence and clinical efficacy of generic versus brand-name medications.

Purpose of the Study:

• To evaluate residual platelet aggregation after switching from generic clopidogrel (GC) to brand clopidogrel (BC).
• To compare the antiplatelet effects of GC and BC in male patients following STEMI.

Main Methods:

• An open-label, prospective cohort study involving 33 male STEMI patients on DAPT (aspirin and GC).
• Patients were switched from GC to BC after two weeks of therapy.
• Platelet aggregation induced by adrenaline and adenosine diphosphate (ADP) was measured before and after the switch.

Main Results:

• Adrenaline-induced platelet aggregation showed no significant difference between GC and BC.
• A statistically significant reduction in 5 µM ADP-induced platelet aggregation was observed after switching to BC (23.9 ± 2.1% vs. 28.0 ± 2.5%, p=0.03).
• A smaller, yet significant, reduction was noted with 20 µM ADP-induced aggregation favoring BC (34.6 ± 2.8% vs. 36.2 ± 2.9%, p=0.04).

Conclusions:

• Switching from GC to BC resulted in a mild but significant decrease in ADP-induced platelet aggregation in male post-STEMI patients.
• The findings warrant confirmation in larger, randomized controlled trials.
• The observed differences may have clinical relevance, particularly in healthcare systems relying heavily on generic clopidogrel for post-MI patients.